[go: up one dir, main page]

AR046188A1 - Sal de colina de la 2-( 3,4-dimetilfenil) -4- ((2- hidroxi-3' -(1h- tetrazol - 5- il) bifenil -3- il) - hidrazono) - 5 metil-2,4- dihidropirazol - 3 ona, composicion farmaceutica que la comprende, uso de la sal de colina para fabricar una composicion farmaceutica, procedimiento para preparar dicha o - Google Patents

Sal de colina de la 2-( 3,4-dimetilfenil) -4- ((2- hidroxi-3' -(1h- tetrazol - 5- il) bifenil -3- il) - hidrazono) - 5 metil-2,4- dihidropirazol - 3 ona, composicion farmaceutica que la comprende, uso de la sal de colina para fabricar una composicion farmaceutica, procedimiento para preparar dicha o

Info

Publication number
AR046188A1
AR046188A1 ARP040103827A ARP040103827A AR046188A1 AR 046188 A1 AR046188 A1 AR 046188A1 AR P040103827 A ARP040103827 A AR P040103827A AR P040103827 A ARP040103827 A AR P040103827A AR 046188 A1 AR046188 A1 AR 046188A1
Authority
AR
Argentina
Prior art keywords
pharmaceutical composition
salt
cells
tetrazol
dimethylphenyl
Prior art date
Application number
ARP040103827A
Other languages
English (en)
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of AR046188A1 publication Critical patent/AR046188A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Psychology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)

Abstract

Un mimético de trombopoyetina mejorado, la sal de colina de la 2-(3,4-dimetilfenil)-4-{[2-hidroxi-3'-(1H-tetrazol-5-il)bifenil-3-il]hidrazono}-5-metil-2,4-dihidropirazol-3-ona. Composición farmacéutica que comprende dicha sal de colina y un vehículo o diluyente farmacéuticamente aceptable. Uso de la sal de colina para fabricar una composición farmacéutica para tratar la trombocitopenia en un mamífero que lo necesite, mediante la administración a dicho mamífero de una cantidad terapéuticamente eficaz de dicha sal. La composición farmacéutica es útil para potenciar la producción de plaquetas en un mamífero. La sal se administra tanto por vía oral como parenteral. La composición farmacéutica sirve para efectuar una actividad agonista del receptor de TPO en un sujeto. Procedimiento para preparar la composición farmacéutica que comprende asociar la sal descrita con un vehículo o diluyente farmacéuticamente aceptable. Un método in vitro o ex vivo para potenciar la estimulación de la maduración de megacariocitos y/o producción de plaquetas; para potenciar la supervivencia y/o proliferación de células madre, células de la médula ósea, células de sangre de cordón umbilical, células de sangre periférica u otros tipos de células que expresan el receptor de TPO en cultivo, o para potenciar la estimulación de producción de neutrófilos; que comprende anadir una cantidad eficaz de dicha sal al medio de cultivo de células madre, células de la médula ósea, células de sangre de cordón umbilical, células de sangre periférica u otros tipos de células que expresan el receptor de TPO. Procedimiento para preparar la sal de colina descripta que comprende: i) disolver la 2-(3,4-dimetilfenil)-4-{[2-hidroxi-3'-(1H-tetrazol-5-il)bifenil-3- il]hidrazono}-5-metil-2,4-dihidropirazol-3-ona en un disolvente o disolventes orgánicos, para formar una solución; ii) anadir uno o más equivalentes de hidróxido de colina a la solución; y iii) aislar el compuesto preparado.
ARP040103827A 2003-10-22 2004-10-21 Sal de colina de la 2-( 3,4-dimetilfenil) -4- ((2- hidroxi-3' -(1h- tetrazol - 5- il) bifenil -3- il) - hidrazono) - 5 metil-2,4- dihidropirazol - 3 ona, composicion farmaceutica que la comprende, uso de la sal de colina para fabricar una composicion farmaceutica, procedimiento para preparar dicha o AR046188A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US51348103P 2003-10-22 2003-10-22

Publications (1)

Publication Number Publication Date
AR046188A1 true AR046188A1 (es) 2005-11-30

Family

ID=34549283

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP040103827A AR046188A1 (es) 2003-10-22 2004-10-21 Sal de colina de la 2-( 3,4-dimetilfenil) -4- ((2- hidroxi-3' -(1h- tetrazol - 5- il) bifenil -3- il) - hidrazono) - 5 metil-2,4- dihidropirazol - 3 ona, composicion farmaceutica que la comprende, uso de la sal de colina para fabricar una composicion farmaceutica, procedimiento para preparar dicha o

Country Status (19)

Country Link
US (1) US7666857B2 (es)
EP (1) EP1684748A4 (es)
JP (1) JP2007509159A (es)
KR (1) KR20060095761A (es)
CN (1) CN1897937B (es)
AR (1) AR046188A1 (es)
AU (1) AU2004285462B2 (es)
BR (1) BRPI0415704A (es)
CA (1) CA2543216A1 (es)
IL (1) IL174924A0 (es)
IS (1) IS8461A (es)
MA (1) MA28113A1 (es)
MX (1) MXPA06004483A (es)
NO (1) NO20062111L (es)
NZ (1) NZ546463A (es)
RU (1) RU2379297C2 (es)
TW (1) TW200526638A (es)
WO (1) WO2005041867A2 (es)
ZA (1) ZA200602901B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CY2010012I2 (el) 2000-05-25 2020-05-29 Novartis Ag Μιμητικα θρομβοποιητινης
MY142390A (en) 2002-05-22 2010-11-30 Glaxosmithkline Llc 3' - [(2z)-[1-(3,4-dimethylphenyl)-1,5- dihydro-3- methyl-5-0xo-4h-pyrazol-4- ylidene]hydrazino]-2' -hydroxy -[1,1' -biphenyl]-3-carboxylic acid bis-(monoethanolamine)
US20090048318A1 (en) * 2003-04-29 2009-02-19 Connie Erickson-Miller Methods for treating degenerative diseases/injuries
US20090143453A1 (en) * 2003-04-29 2009-06-04 Connie Erickson-Miller Methods for treating degenerative diseases/injuries
US20090298179A1 (en) * 2003-04-29 2009-12-03 Connie Erickson-Miller Methods For Treating Degenerative Diseases/Injuries
US20070105824A1 (en) * 2003-04-29 2007-05-10 Erickson-Miller Connie L Methods for treating degenerative diseases/injuries
US20100004302A1 (en) * 2003-04-29 2010-01-07 Connie Erickson-Miller Methods for Treating Degenerative Diseases/Injuries
TW200526638A (en) 2003-10-22 2005-08-16 Smithkline Beecham Corp 2-(3,4-dimethylphenyl)-4-{[2-hydroxy-3'-(1H-tetrazol-5-yl)biphenyl-3-yl]-hydrazono}-5-methyl-2,4-dihydropyrazol-3-one choline
US20070031373A1 (en) * 2005-08-04 2007-02-08 Carlos Lopez Reversal of Adult Onset Disorders with Granulocyte-Colony Stimulating Factors
JP2009511603A (ja) * 2005-10-13 2009-03-19 スミスクライン・ビーチャム・コーポレイション 貯蔵中の血小板の有効性を維持する方法
US7879318B2 (en) 2006-01-23 2011-02-01 Mcw Research Foundation, Inc. Method of reducing the effects of ischemia by administration of a thrombopoietin receptor ligand
GB0603522D0 (en) * 2006-02-22 2006-04-05 Avidex Ltd Kinase inhibition
ECSP077628A (es) 2007-05-03 2008-12-30 Smithkline Beechman Corp Nueva composición farmacéutica
PL3127427T3 (pl) 2009-05-29 2020-06-15 Novartis Ag Sposoby podawania związków agonistów trombopoetyny
RU2469763C1 (ru) * 2011-11-16 2012-12-20 Анатолий Степанович Дресвянкин Коньколыжи
BR112017026406A2 (pt) 2015-06-12 2019-04-02 Adhaere Pharmaceuticals, Inc. formas sólidas de ácido (z)-4-(5-((3-benzil-4-oxo-2-tioxotiazolidin-5-ilideno)metil)furan-2-il)benzoico

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE193350C (es)
US851444A (en) * 1905-11-13 1907-04-23 Agfa Ag Amido-oxy-sulfonic acid of phenylnaphthimidazol and process of making same.
GB779880A (en) 1953-02-27 1957-07-24 Ciba Ltd Functional derivatives of azo-dyestuffs containing sulphonic acid groups and processfor making them
GB826207A (en) 1956-07-23 1959-12-31 Bayer Ag ú´-ú´-dihydroxy-monoazo dyestuffs containing pyrrolidonyl residues and their metal complex compounds
US2950273A (en) * 1956-11-20 1960-08-23 Agfa Ag Process for the production of symmetrical and unsymmetrical azo compounds
US3366619A (en) * 1965-04-09 1968-01-30 Interchem Corp Disazo pyrazolone pigments
US4435417A (en) * 1981-02-20 1984-03-06 Gruppo Lepetit S.P.A. Antiinflammatory 3H-naphtho[1,2-d]imidazoles
ES523609A0 (es) * 1982-07-05 1985-03-01 Erba Farmitalia Procedimiento para preparar derivados n-imidazolilicos de compuestos biciclicos.
FI91869C (fi) * 1987-03-18 1994-08-25 Tanabe Seiyaku Co Menetelmä antidiabeettisena aineena käytettävien bensoksatsolijohdannaisten valmistamiseksi
US4880788A (en) * 1987-10-30 1989-11-14 Baylor College Of Medicine Method for preventing and treating thrombosis
WO1993017681A1 (en) 1992-03-02 1993-09-16 Abbott Laboratories Angiotensin ii receptor antagonists
GB9205320D0 (en) * 1992-03-11 1992-04-22 Ici Plc Anti-tumour compounds
IL109570A0 (en) 1993-05-17 1994-08-26 Fujisawa Pharmaceutical Co Guanidine derivatives, pharmaceutical compositions containing the same and processes for the preparation thereof
EP0638617A1 (de) 1993-08-13 1995-02-15 Ciba-Geigy Ag Pigmentsalze
US5532202A (en) * 1993-12-28 1996-07-02 Dai Nippon Printing Co., Ltd. Thermal transfer sheet
US5482546A (en) * 1994-03-30 1996-01-09 Canon Kabushiki Kaisha Dye, ink containing the same, and ink-jet recording method and instrument using the ink
FR2725987B1 (fr) * 1994-10-19 1997-01-10 Sanofi Sa Procede pour la preparation d'un derive de tetrazole sous deux formes cristallines et nouvelle forme cristalline de ce derive
RU2144533C1 (ru) * 1994-12-09 2000-01-20 Такеда Кемикал Индастриз, Лтд. Производные тетразола, способ их получения и фармацевтические композиции на их основе
US5760038A (en) * 1995-02-06 1998-06-02 Bristol-Myers Squibb Company Substituted biphenyl sulfonamide endothelin antagonists
US5746821A (en) * 1995-02-13 1998-05-05 Engelhard Corporation Pigment compositions
KR100436680B1 (ko) 1995-06-07 2004-09-18 글락소 그룹 리미티드 트롬보포이에틴 수용체에 결합하는 펩티드 및 화합물
US5622818A (en) * 1995-11-29 1997-04-22 Eastman Kodak Company Color photographic elements containing yellow colored magenta dye forming masking couplers
US5669967A (en) * 1996-05-30 1997-09-23 Engelhard Corporation Pigment compositions
US5932546A (en) * 1996-10-04 1999-08-03 Glaxo Wellcome Inc. Peptides and compounds that bind to the thrombopoietin receptor
SE9701398D0 (sv) 1997-04-15 1997-04-15 Astra Pharma Prod Novel compounds
GB9715830D0 (en) * 1997-07-25 1997-10-01 Basf Ag Reactive dyes containing piperazine
WO1999011262A1 (en) 1997-09-02 1999-03-11 Roche Diagnostics Gmbh Mpl-receptor ligands, process for their preparation, medicaments containing them and their use for the treatment and prevention of thrombocytopaenia and anaemia
GB9718913D0 (en) 1997-09-05 1997-11-12 Glaxo Group Ltd Substituted oxindole derivatives
AU738473B2 (en) * 1997-10-31 2001-09-20 Glaxosmithkline Llc Novel metal complexes
DE19851389A1 (de) * 1998-11-07 2000-05-11 Dystar Textilfarben Gmbh & Co Gelbe Farbstoffmischungen von wasserlöslichen faserreaktiven Azofarbstoffen und ihre Verwendung
GC0000177A (en) 1998-12-17 2006-03-29 Smithkline Beecham Thrombopoietin mimetics
KR20020069183A (ko) 1999-07-26 2002-08-29 시오노기세이야쿠가부시키가이샤 트롬보포이에틴 작동성을 나타내는 의약 조성물
JP4488663B2 (ja) 1999-09-10 2010-06-23 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー トロンボポイエチン模倣物
WO2001021180A1 (en) 1999-09-24 2001-03-29 Smithkline Beecham Corporation Thrombopoietin mimetics
JP2003513965A (ja) 1999-11-05 2003-04-15 スミスクライン・ビーチャム・コーポレイション セミカルバゾン誘導体およびそれらのトロンボポエチン模倣物としての使用
ES2160560T1 (es) 1999-11-10 2001-11-16 Curacyte Ag Colorantes o,o'-dihidroxi-azoicos como constituyentes de medicamentos para el tratamiento de trombopenias.
TWI284639B (en) 2000-01-24 2007-08-01 Shionogi & Co A compound having thrombopoietin receptor agonistic effect
US6436915B1 (en) * 2000-04-07 2002-08-20 Kinetek Pharmaceuticals, Inc. Pyrazole compounds
US6214813B1 (en) * 2000-04-07 2001-04-10 Kinetek Pharmaceuticals, Inc. Pyrazole compounds
CY2010012I2 (el) * 2000-05-25 2020-05-29 Novartis Ag Μιμητικα θρομβοποιητινης
CA2436288A1 (en) 2000-12-19 2002-06-27 Smithkline Beecham Corporation Thrombopoietin mimetics
CA2432800A1 (en) 2000-12-21 2002-07-25 Smithkline Beecham Corporation Regulated activation of cell-membrane receptors by metal-chelating agonists
JP4145655B2 (ja) * 2001-01-26 2008-09-03 塩野義製薬株式会社 トロンボポエチン受容体アゴニスト作用を有するハロゲン化合物
WO2002059099A1 (en) 2001-01-26 2002-08-01 Shionogi & Co., Ltd. Cyclic compounds having thrombopoietin receptor agonism
WO2002085343A1 (en) 2001-03-01 2002-10-31 Smithkline Beecham Corporation Thrombopoietin mimetics
US7105824B2 (en) * 2002-05-09 2006-09-12 Neurologica, Corp. High resolution photon emission computed tomographic imaging tool
JP3927001B2 (ja) 2001-06-15 2007-06-06 三菱化学株式会社 色素セット、インクセット並びに記録方法
WO2003045379A1 (en) 2001-11-30 2003-06-05 Kinetek Pharmaceuticals, Inc. Hydrazonopyrazole derivatives and their use as therapeutics
US20040176372A1 (en) 2002-03-01 2004-09-09 Pintex Pharmaceuticals, Inc. Pin1-modulating compounds and methods of use thereof
MY142390A (en) 2002-05-22 2010-11-30 Glaxosmithkline Llc 3' - [(2z)-[1-(3,4-dimethylphenyl)-1,5- dihydro-3- methyl-5-0xo-4h-pyrazol-4- ylidene]hydrazino]-2' -hydroxy -[1,1' -biphenyl]-3-carboxylic acid bis-(monoethanolamine)
WO2003103686A1 (en) 2002-06-06 2003-12-18 Smithkline Beecham Corporation Thrombopoietin mimetics
JP2006514951A (ja) 2002-12-13 2006-05-18 スミスクライン・ビーチャム・コーポレイション トロンボポエチン模倣物
US20070105824A1 (en) 2003-04-29 2007-05-10 Erickson-Miller Connie L Methods for treating degenerative diseases/injuries
TW200526638A (en) 2003-10-22 2005-08-16 Smithkline Beecham Corp 2-(3,4-dimethylphenyl)-4-{[2-hydroxy-3'-(1H-tetrazol-5-yl)biphenyl-3-yl]-hydrazono}-5-methyl-2,4-dihydropyrazol-3-one choline

Also Published As

Publication number Publication date
TW200526638A (en) 2005-08-16
WO2005041867A8 (en) 2006-07-06
RU2006117313A (ru) 2007-11-27
RU2379297C2 (ru) 2010-01-20
IL174924A0 (en) 2006-08-20
ZA200602901B (en) 2008-02-27
MA28113A1 (fr) 2006-08-01
AU2004285462B2 (en) 2010-05-27
EP1684748A4 (en) 2009-12-09
IS8461A (is) 2006-05-12
US20070072922A1 (en) 2007-03-29
AU2004285462A1 (en) 2005-05-12
CA2543216A1 (en) 2005-05-12
EP1684748A2 (en) 2006-08-02
MXPA06004483A (es) 2006-06-20
NZ546463A (en) 2009-08-28
NO20062111L (no) 2006-07-18
KR20060095761A (ko) 2006-09-01
US7666857B2 (en) 2010-02-23
CN1897937B (zh) 2010-11-24
JP2007509159A (ja) 2007-04-12
WO2005041867A3 (en) 2005-10-13
CN1897937A (zh) 2007-01-17
WO2005041867A2 (en) 2005-05-12
BRPI0415704A (pt) 2006-12-19

Similar Documents

Publication Publication Date Title
AR046188A1 (es) Sal de colina de la 2-( 3,4-dimetilfenil) -4- ((2- hidroxi-3' -(1h- tetrazol - 5- il) bifenil -3- il) - hidrazono) - 5 metil-2,4- dihidropirazol - 3 ona, composicion farmaceutica que la comprende, uso de la sal de colina para fabricar una composicion farmaceutica, procedimiento para preparar dicha o
AR040083A1 (es) Compuesto bis-(monoetanolamina) del acido 3'-[(2z)-[1-(3,4-dimetilfenil) -1,5-dihidro-3-metil-5-oxo-4h-pirazol-4-iliden] hidrazino] -2'-hidroxi-[1,1'-bifenil]-3-carboxilico, procedimiento para prepararlo, composicion farmaceutica que lo comprende, procedimiento para preparar dicha composicion farmac
TWI305207B (en) Thrombopoietin mimetics
EP4352206A2 (en) Liver organoid model for hyperbilirubinemia and methods of making and using same
RU2013119129A (ru) Органические соединения
JP2011504903A5 (es)
JP2010527368A5 (es)
RU2010121160A (ru) Спиросоединения и их фармацевтическое применение
KR102577669B1 (ko) 이식 후에 조혈 줄기 세포의 생착 효능을 증가시키는데 사용하기 위한 조성물
AR062536A1 (es) Acilanilidas sustituidas y composicion farmaceutica
WO2006064757A1 (ja) アミノカルボン酸誘導体およびその医薬用途
Chang et al. Ex-vivo generation of drug-eluting islets improves transplant outcomes by inhibiting TLR4-Mediated NFkB upregulation
UY31554A1 (es) Nuevos inhibidores de acetil coenzima a carboxilasa y usos en tratamientos de obesidad y diabetes mellitus
US20220073880A1 (en) Natural killer cells
MX2023005533A (es) Derivado de triazina diona, metodo de preparacion y aplicacion del mismo en medicina.
AR043822A1 (es) Formas de dosificacion y procedimientos de tratamiento que usan inhibidores del vegfr
AU2015362089A1 (en) Dislodgement and release of HSC using alpha 9 integrin antagonist and CXCR4 antagonist
EP2849743A1 (en) Cancer cell inhibitory drug and cancer stem-cell detection probe
Estacion et al. Blockade of maitotoxin-induced endothelial cell lysis by glycine and L-alanine
CA2446622A1 (en) Isostearic acid salts as permeation enhancers
BRPI0507657A (pt) composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, método para tratar um distúrbio, e, uso de um composto ou um sal farmaceuticamente aceitável do mesmo
DE102004054545A1 (de) Änderung des Beladungszustandes von MHC-Molekülen
IL237119A (en) Heterocyclic carboxamides for the treatment of viral diseases
KR102411834B1 (ko) 이식 결과 개선 및 췌장 세포 건강, 생존 향상을 위한 항-노화 글리코펩타이드들의 용도
WO2014144125A1 (en) Compounds for inducing proliferation and differentiation of cells, and methods of use thereof

Legal Events

Date Code Title Description
FA Abandonment or withdrawal